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EARLY DIAGNOSIS OF RELAPSE IN BORDERLINE LEPROSY: TWO CASE REPORTS
Maria Luiza Figueiredo Braga BRANDÃO(1), Cíntia Maria Oliveira LIMA(1), Juan PIÑEIRO-MACEIRA(1), Alice MIRANDA(2) & M.Leide W. de OLIVEIRA(1)
SUMMARY
Two cases of relapse in borderline leprosy were reported. Despite the late-reversal, reaction-like feature, the suspicion of relapse 
in both was based on persistent and slow-developing skin lesions and an absence of acute neuritis or reaction during one year of 
follow-up. The authors have considered this possible occurrence in lepromatous borderline-treated patients after their immune cellular 
restoration and defend that not all Type 1 reactions would be an inflammatory answer to persistent Mycobacterium leprae, but that 
they could be. Therefore, a relapse diagnosis could be applied and it is more advisable, as one year of Multi-Drug Therapy (MDT) is 
less dangerous and more efficient for these cases than one year of corticosteroids.
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INTRODUCTION
The proven efficiency of WHO Multi-drug therapy has been given 
low importance in recent decades due to low relapse2. The diagnosis of 
late multibacillary leprosy (LL, BL) is not difficult, neither clinically or 
in the laboratory, due to the presence of acid fast bacilli6. However, the 
diagnosis of leprosy relapses on the borderline spectrum (BT,BB) in 
field conditions is complex and has taught leprologists many lessons, as 
many of these cases may present features similar to reversal reaction at 
the onset. For an illness like leprosy, with multiple clinical presentations 
without definitive knowledge of its immunopathologic aspects, nothing 
is more concrete for learning opportunities than the clinical disease 
manifestation in man as illustrated in the following cases.
CASE REPORTS
Two cases of borderline lepromatous leprosy were diagnosed, treated 
and followed up after being released by cure in the University Hospital 
of the Federal University of Rio de Janeiro (UFRJ). Both had clinical 
and histopathological confirmation and received MDT for MB leprosy. 
Case 1 returned only once during the 5-year period after having been 
released and case 2 was under surveillance while presenting a Type 1 
Reversal Reaction (RR) during seven years.
Case 1: 31-year-old male, diagnosed with BL leprosy in 1998 and 
treated regularly with 12 doses of MDT and released without clinical 
lesions and grade 0 physical disability in 1999. Returned once with 
one episode of RR, two years after being released, without recurrence. 
In 2006, returned with macular lesions diagnosed as macular RR. As 
the lesion became infiltrated without any other symptoms and signs 
of reaction, there was a suspicion of relapse (Fig. 1). Serology and 
slit skin smears were negative, but biopsy revealed a slight infiltration 
of lymphocytes and histiocytes around blood vessels, and fragmented 
acid fast bacilli inside nerves (Fig. 2). Despite doubts concerning the 
diagnosis of RR or relapse, the decision was to re-treat this patient since 
no clinical sign of reaction was observed. After 12 doses of MDT all 
lesions disappeared and the patient has not shown any reaction since his 
release in the beginning of 2007.
Case 2: 66-year-old male, diagnosed with BL leprosy in 2001, 
regularly treated with 12 doses of MDT and released presenting RR and 
grade 1 physical disability. Many courses of steroids were prescribed 
during seven years, always initiating with 1 mg/kg. The persistence of 
RR lesions and worsening of parestesia in the ulnar nerve prompted 
the relapse investigation, with skin smears showing negative results 
and histopathology showing one acid-fast bacillus and without any 
granulomatous process, anti-PGL1 serology 2+/4. The decision was 
to maintain close observation of the patient, without corticosteroid, 
during the full year of 2009. After 10 months the lesions became more 
infiltrated (Fig. 3-4), the parestesia symptoms increased, serology also 
increased to 3+++/4; PCR sequencing of ML was +, but skin smears 
were continuously negative. The histopathological examination showed 
perineural epithelioid granulomas (Fig. 5). The patient was diagnosed 
with early borderline relapse, and a new MDT/MB regimen was then 
started (Fig. 6).
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Fig. 3 - Patches and paresthesy in the trunk and positive serology test (AntiPGL-1) in 2009.
Fig. 4 - Patches and paresthesy in the buttocks.
Fig. 2 - Wade X1000-AFB fragmented within nerve bundles. Fig. 5 - HEX 400X - Periadnexal granulomatous infiltrate.
DISCUSSION
The clinical cure of leprosy has been defined as the normalization 
which considers that six fixed doses cure paucibacillary cases and 
12 doses cure multibacillary cases. These criteria were based on the 
distinction between the infectious disease due to M. leprae and the 
secondary inflammatory disease caused by host response to intracellular 
parasitism. The current treatment regimes are strong enough to kill M. 
leprae and stop disease transmission. However, signs and symptoms 
persist in approximately 30% of cases for an indeterminate period4. It is 
well known that in treated leprosy patients, some persistent mycobacteria 
remain in latent form1,5,8,10. Whether this fact can be related to late 
reactions is still a controversial issue3.
According to OPROMOLLA, 20017, Type 1 reaction is related to 
persistent Mycobacterium leprae multiplication “it is not logical that 
similar clinical manifestations known to have happened before, during 
or after treatment should be considered so differently”. WATERS, 2001, 
also considers this possibility, especially in BL-treated patients after 
immune cellular restoration9,10.
The authors of this report state that not all Type 1 reactions are an 
Fig. 1 - Disseminated patches and paresthesia.
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Fig. 6 - Skin lesion improvement seven months after the MDT-Biopsy .
inflammatory answer to persistent Mycobacterium leprae, but that they 
could be.
The two cases presented here had BL leprosy in common, and also 
the reappearance of BT leprosy after different evolutions: case one was 
cured and went five years without skin and nerve lesions while case 
2 maintained skin lesions for the whole surveillance period. After the 
suspicion of relapse, both showed persistent and slow-developing skin 
lesions and an absence of acute neuritis or any acute reaction during one 
year of follow-up.
The careful histopathologic examination found one AFB in case 1 
(Fig. 2). How can we explain multiple fragmented bacillus after such a 
long period since being cured of borderline leprosy?
In case 2, the strong Anti-PGL1 serology also could not be 
explained seven years after treatment and a solid AFB was found in 
an histopathological exam. Three experienced pathologists examined 
these samples.
Neither patient had had a second leprosy case in the family, despite the 
fact that both patients live in a region endemic for leprosy. Furthermore, 
in both patients the second course of MDT/MB was successful, which 
reinforces that in some late RR-like episodes with slow evolution, a 
leprosy relapse diagnosis could be applied. This is even more advisable 
because one year of MDT could be less dangerous and more efficient 
than one year of corticosteroids.
RESUMO
Diagnóstico precoce de recidiva em hanseníase dimorfa: 
apresentação de dois casos
São apresentados dois casos de recidiva de hanseníase borderline. 
Apesar das características de reação reversa tardia, a suspeita de recidiva 
foi baseada no desenvolvimento insidioso e persistente de lesões 
cutâneas sem reação e neurite agudas, durante um ano de seguimento. Os 
autores consideram a possibilidade de recidiva em pacientes borderline 
virchowinano tratados, pela restauração da imunidade celular e postulam 
que embora nem toda reação tipo 1 seja devida a presença de M. leprae 
persistentes, isso também pode ocorrer. Assim, o diagnóstico de recidiva 
foi considerado ressaltando-se que um ano de poliquimioterapia oferece 
menos danos e pode ser mais eficiente nesses casos, que um ano de 
corticosteróides.
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